Skip to content

Royalty Pharma RPRX Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Operating margin294.6%+84.5pp210.1%
Net margin157.7%+3.4pp154.3%
Returns
Return on equity37.2%+2.2pp34.9%
Return on invested capital41.2%+11.0pp30.2%
Efficiency
Asset turnover0.5×0.0×0.5×0.0×0.6×0.0×0.5×
Liquidity
Current ratio8.7×-16.1×24.8×-1.4×26.3×-19.1×45.4×-1.2×
Leverage
Debt-to-equity3.5×+0.6×2.9×+0.2×2.7×-0.1×2.8×+0.3×
Per Share
Book value per share$68.22+1.0%$67.56+3.9%$65.04-10.6%$72.75-3.2%
Valuation
Market capitalization$60.48B+22.2%$49.5B-9.1%$54.48B-22.5%$70.3B+1.9%
Price / earnings68.5×+9.6×59×
Price / sales26×+4.0×22×-1.2×23.2×-8.0×31.2×+0.5×
Price / book6.3×+1.3×4.9×-0.6×5.5×-1.4×+0.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Royalty Pharma's ratios come from?
Every ratio is computed from Royalty Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.